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A qualitative synthesis of pharmacist, other health professional and lay perspectives on the role of 
Community Pharmacy in facilitating care for people with long-term conditions. 
ABSTRACT 
Background: There is increasing interest in an enhanced role for community pharmacy (CP) in facilitating 
care for people with long-term conditions (LTCs).  It is important to understand the perspectives of 
stakeholders in order to identify key issues that may impact on future development of the role and 
related services.   
Objectives: Explore pharmacist, other health professional and lay perspectives on the role of CP in 
facilitating care for people with LTCs.  
Methods: Synthesis of qualitative research from UK based studies published between 2007 and January 
2017 using a meta-ethnographic interpretative approach.  
Results: Variation in the conceptualisation of the role of CP in facilitating the care of people with LTCs 
was apparent across and within lay and health professional accounts. Despite evidence of positive 
attitudes and a culture amenable to change, there remains a lack of clarity about the existing and 
potential role of the pharmacist in this area. A theoretical framework is proposed that highlights the 
dynamic nature of the process involved in the development of lay and health professionals’ 
understanding of the role and engagement with services. Influences on this process include experience 
and perceived need, service operationalisation, and ongoing developments within wider healthcare 
policy and commercial environments. Perceived integration with existing professional and peer support 
structures, views about traditional medical hierarchies and concerns about potential duplication are 
important influences on the value attributed to the role of CP and the services provided.  
Conclusions: There is acknowledged potential for an extended role in CP to support the care of people 
with LTCs. To ensure the likelihood of successful engagement with patients and positive health 
outcomes, developments should acknowledge influences within and beyond the CP setting. Potential 
overlap with other healthcare services should be explicitly addressed, ensuring this is framed and 
delivered as valued reinforcement with clearly defined boundaries of responsibility. 
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A qualitative synthesis of pharmacist, other health professional and lay perspectives on the role of 
Community Pharmacy in facilitating care for people with long-term conditions. 
INTRODUCTION 
The increasing burden associated with long-term conditions (LTCs) is one of the biggest challenges facing 
healthcare systems worldwide.  In the United Kingdom (UK), LTCs account for 70% of health and social 
care spending and 50% of all General Practitioner (GP) appointments, and the number of people living 
with complex multi-morbidities is rising rapidly.1 2  Due to a growing and aging population and increasing 
financial pressure on the UK’s National Health Service (NHS), there is an urgent need to understand how 
best to help support the growing number of people with LTCs to self-manage their conditions, 1 3 whilst 
delivering high quality and affordable care as envisaged in the NHS Five Year Forward View. 2 4  
Community pharmacy (CP) already plays a significant role in the ongoing monitoring, support and 
treatment of people living with LTCs. 5   CP-led interventions have been shown to have a positive effect 
on the identification of undiagnosed LTCs, their management and clinical outcomes .6-9 CP’s convenience 
and easy access, particularly in areas of higher deprivation, means that it is ideally placed to provide 
services that can help support those most in need. 10   Furthermore, an extended role for CP in the 
prevention and management of LTCs has been identified by policy makers internationally alongside calls 
for the provision of more “cognitive” and “clinical” services to support both medicines use and public 
health. 11 12   Pharmacy contractual arrangements vary between different countries within the UK.  In 
England, the Community Pharmacy Contractual Framework, first introduced in 2005, allows pharmacies 
to be reimbursed for providing a range of NHS services.  Currently, the main contracted services to 
support people with LTCs are medicines use reviews (MURs) and the New Medicine Service (NMS), 
targeted at chronic respiratory and cardiovascular diseases. CP also has a defined public health role that 
includes a responsibility for supporting patients with LTCs with lifestyle advice. 13-15   In Scotland, LTC 
support is provided by the Chronic Medication Service (CMS).  Although services such as MURs, NMS, 
and CMS are operationalised differently across the UK, they all allow for the provision of support for 
LTCs beyond the traditional dispensing role of pharmacists.   
 It is argued, however, that the full potential of CP to contribute to increasing demand on stretched NHS 
resources has yet to be realized; that progress in extending the role of community pharmacists (CPs) has 
been “patchy and lacking in scale;” and that there is still untapped potential for their role in the wider 
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contribution to the “prevention, early detection, supported self-care and ongoing management of LTCs”. 
12 16-18  
CP professional organisations and bodies in the UK have recently published a shared vision document 
that proposes the facilitation of personalized care for people with LTCs as one of the key areas in which 
CP has the potential to make a significant contribution to addressing the needs of an already 
overburdened health and care system. 18 19   A number of challenges have been identified to the 
successful implementation of this vision, including funding and regulation requirements; systematic and 
wider integration of CP within new models of care currently being developed within the NHS more 
widely; greater “digital maturity and interconnectivity” with improved access to healthcare records; 
consideration of NHS and CP organisational cultures; and increased public awareness. 1 2 4 16    
Exploration of the perceptions of patients, community pharmacists and other relevant stakeholders is 
important to help understand and assess how to ensure that any service developments and innovations 
in this area will meet the needs of, and be acceptable to, people with LTCs and their carers, community 
pharmacists and the health professionals with whom they work.  Although evidence suggests that 
patients with LTCs value aspects of extended CP services 20 and that their experiences of service 
provision can improve attitudes towards pharmacists and subsequent interactions, findings are 
conflicting and patient satisfaction is closely linked to expectations and beliefs in relation to the 
legitimacy of an extended CP role. 21  Findings from qualitative research are helpful in providing a more 
in-depth understanding of these issues; however, these studies tend to focus on specific CP services, 
LTCs or stakeholder groups.  The value of synthesizing the results of quantitative research in building a 
cumulative knowledge base is well established; however, the accepted methods used for this are not 
applicable to qualitative research.22  This study aimed to use an interpretative meta-ethnographic 
approach 22-24  to synthesise and interpret findings from existing qualitative studies in order to develop 
additional insight into how the role of CP in facilitating care for people with LTCs is perceived.  
METHODS 
Qualitative research findings from UK-based studies published between 2007 and January 2017 were 
synthesized using an inductive and interpretative approach in line with Noblit and Hare’s method of 
meta-ethnography. 22-24   This approach involves translation and synthesis of key “interpretative 
metaphors” (themes, perspectives or concepts) across empirical research studies using a continuous 
comparative analysis of texts while preserving original meanings and exploring the contexts in which 
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these are understood.   Meta-ethnography differs from other more descriptive methods of qualitative 
synthesis in that it aims to build on the second order interpretations and explanations from original 
research, which are treated as data, to develop new interpretations and a more comprehensive 
understanding of a particular phenomenon.25 Specifically, in this case, this method is used to understand 
beliefs about the potential of the role of CP in facilitating the care of people with LTCs.  Although initially 
developed for the synthesis of ethnographies, this method is now used more widely in health-related 
research, incorporating qualitative studies from a range of research traditions that focus on in-depth 
accounts of people’s experiences, perceptions, social interactions and behaviours.     
 
Literature search 
A systematic literature search was conducted in February 2017 to identify peer reviewed qualitative 
research papers published from 2007 to 2017.  PubMed (including Medline), EMBASE and CINAHL 
databases were searched using key terms across five areas, including derivatives and thesaurus terms 
adapted for the requirements of each database.  These included the following:  Community pharmacy or 
pharmacist, qualitative methods, lay and health professional perspectives, roles or services, chronic 
disease or long-term conditions. Hand searching of reference lists of all relevant papers identified was 
also completed.  Inclusion and exclusion criteria can be found in table 1.   
(insert Table 1) 
The search was restricted to primary research papers published in peer reviewed journals.   Only studies 
from the UK were included to ensure comparability in terms of the associated healthcare and socio-
political systems within which the study findings were situated, thereby facilitating a more in-depth 
exploration of the specific cultural context in which CP operates.  The search included terms associated 
with services commissioned across the UK, such as MURs, NMS and CMS.  Evidence relating to these 
services are likely to be transferable and of relevance to people living with LTCs and those who help to 
support their care.    
 
A restriction to the last 10 years was implemented to help ensure that findings would be as relevant as 
possible to the current economic and healthcare context within the UK, while acknowledging potential 
for change over time.   
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It is common within meta-ethnographies to purposively sample relevant papers based on maximal 
variation sampling,23 or iteratively until theoretical saturation is achieved. 26   Due to the limited number 
of papers identified,  all were included in the analysis further to a quality appraisal using the Critical 
Appraisal Skills Programme (CASP) checklist. 27  All included papers were deemed to have used 
appropriate methods to address the stated aims of their research, to have appropriate recruitment and 
data collection strategies and have taken ethical issues into consideration.  Papers varied in the depth of 
their analysis and conceptual richness of their findings, but all were considered to be sufficiently 
rigorous and relevant for inclusion.  The ENTREQ checklist (enhancing the transparency in reporting the 
synthesis of qualitative research) was used to ensure systematic reporting. 26  
Analysis 
An inductive and iterative approach to analysis was employed.  Papers were read to identify overarching 
commonalities, differences and shared concepts using constant comparison methods.23   Particular 
attention was paid to the concepts and themes that may be generic across clinical conditions in 
comparison to those that may be condition-specific and to the contexts in which the original data sets 
were collected and interpreted.  First and second order constructs from the results, discussion and 
conclusion sections of the papers were included within the analysis.  Findings from different 
perspectives (patients, public, CP, general practice and other stakeholders) were initially coded 
separately and then compared.  
An initial coding frame was developed and applied to all the selected papers with the help of NVivo 
software so that instances of each newly developed concept were grouped together to aid translation 
and synthesis.  NH (social sciences researcher) coded all the papers and GD (academic community 
pharmacist) dual coded a selection of papers.  Researcher coding and translation across studies was 
compared and adjustments were made to the coding framework and interpretation where appropriate.  
The final interpretation and synthesis of the findings were reviewed by both NH and GD.   
FINDINGS 
A total of 17 papers were identified that met the inclusion and exclusion criteria of the literature search 
(see Figure 1).   
(Insert Figure 1) 
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Included papers represented appropriate variation in terms of the range of methods, perspectives, 
services and medical conditions.  Twelve papers included the views of pharmacists, two of GPs, three of 
other health professionals and eight of patients or carers.   Eight were related to specific services (four 
to the NMS, four to MURs), seven were condition specific (three coronary or heart conditions, two 
dementia, one juvenile arthritis, and one diabetes) and two were based on LTCs more generally.  Most 
papers provided mainly descriptive accounts based on thematic analyses.  A few, however,  based their 
analyses on existing theoretical frameworks, including Normalisation Process Theory 28,  Damschroders’ 
consolidated framework for implementation research 29, Donabedian’s structure-process-outcome 
approach 30 and Foucault’s concept of pastoral power. 31  Summaries of the papers and their 
methodologies are included in tables 2 and 3.   
(Insert Tables 2 and 3) 
Four key overlapping constructs were identified by translating and combining primary data and 
secondary concepts from individual studies i.e. reciprocal translation24. These are described in detail 
below.   Table 4 provides an example of the analytical process and Figure 2 outlines a proposed 
theoretical framework to illustrate the overlap between the constructs, the reciprocal relationship 
between them and the dynamic nature of the process.   Identifiers are provided after data extracts to 
demonstrate whether they relate to lay (Lay), GP (GP), Community Pharmacist (CP) or other health 
professional (HP) accounts, whether the study from which it was extracted was focused on a specific 
service (MUR, NMS or CMS), a combination of LTCs (LTC), or a specific LTC (LTC name) and whether the 
extract originates from a primary data source (primary) or secondary concept (secondary). 
(Insert Table 4) 
(Insert Figure 2)    
Construct 1 - Conceptualisation, disruption and adaptation 
Ongoing national policy developments in the UK and increasingly competitive retail environments have 
resulted in a dynamic shift or disruption to what has been described as the “traditional” or “old school” 
CP dispensing role. 32   Wide variation in the understanding and conceptualisation of the role of CP in 
facilitating the care of people living with LTCs was apparent within and across the lay and health 
professional accounts included within our synthesis.  A range of influences on the understanding, 
acceptance and awareness of changing roles and ways of working within CP in relation to supporting 
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patients with LTCs were described.  These operated at various levels and although some were shared 
between patients and health professionals, others were specific to each group (See Table 5).    
(Insert Table 5)  
Pharmacist and other health professional perspectives 
The accounts of CPs across all studies confirmed the perceived value and opportunity within the existing 
or potential role of CP in supporting people with LTCs.  Perceived benefits included reducing pressure on 
GP 33;  improving the profile and professional status of CP31-35;  patient monitoring and education 29 35;  
improved clinical outcomes 33 35 and perceived patient reassurance and satisfaction. 34 35  
There was also evidence of a culture amenable and accepting of change,34 35  whereby extension to the 
traditional dispensing role is valued and desired, perceived to meet patient need, contributes to job 
satisfaction 28 29 35 and helps to demonstrate the worth and skills of the CP profession.31 32 35  
“I felt like I was in a production factory just checking scripts.  I wanted to be challenged more. 
This [NMS] is doing exactly that and I love my job now, I love doing all these services and I love 
the patient interaction” (CP, NMS, Primary; Wells et al., 2014) 
At the same time, contradictions and uncertainties were also apparent.  Ambiguity of the CP role and 
professional identity, a lack of clarity over responsibilities and a reluctance to engage with additional 
extended roles were also described.  Specific issues centred on:  the lack of perceived value or 
effectiveness of NMS in addressing non-adherence over and above routine advice already provided 29; 
concerns about possible overlap with other healthcare providers33-35;  selective patient eligibility for the 
NMS35;   services being completed in some instances without a definitive patient need and beliefs that 
public awareness and understanding of the services and skills available was low 13;   variable willingness 
to relinquish traditional dispensing roles in order to meet imposed MUR targets and extend existing CP 
roles 32;  and cautious optimism about the ability of CP to transition from dispensing to a patient-centred 
approach. 33  
 “the key challenge for community pharmacists lies in how to combine new roles and make the 
transition from their traditional dispensing roles and responsibilities to a patient-centred self-
care support role” (CP, LTC, secondary; Ogunabayo et al., 2015) 
There was little evidence on the perceptions of GPs and other healthcare providers on the role of CP in 
supporting the care of people with LTCs.  This was despite reports that poor relationships with GPs, 
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discussed in more detail in the following section, was seen to be a key barrier to the integration of the 
role of the CP within the wider healthcare context and the successful implementation of services.  There 
was evidence of recognition by GPs that the skills of the pharmacist are under-utilised, 36 however 
awareness and understanding of the purpose of services such as NMS and MURs were reported to be 
low and had little influence on their practice.29 32   GPs reported concerns about possible duplication of 
work and changes to traditional healthcare boundary divisions. 29 32    
Lay perspectives 
Patients were reported to hold primarily traditional views regarding the division of labour in healthcare 
37-39  and the dominant perception of CP was seen to be responsibility for medicines supply and over the 
counter advice for self-limiting conditions.36 38-40   There was evidence of a lack of clarity about the role 
of the pharmacist or purpose of CP services, 40  particularly when these contradicted expected and 
traditional perceptions of the pharmacist encounter.31 38  
“I wouldn’t necessarily go to my pharmacist and ask about my health around my diabetes, I 
would go and ask, I have got a raging cold, can I take this? And that’s where I find the 
pharmacists really helpful” (Lay, Diabetes, primary; Twigg et al., 2013) 
The role of the pharmacist was usually conceptualized, not in isolation, but in relation to beliefs about 
other roles and responsibilities within the wider healthcare system, primarily those of the GP.  There 
were, nevertheless, positive examples indicating that some patients welcomed LTC support from CPs.  
Patients were reported to perceive CPs as appropriately skilled professionals, 37-39 able to provide 
medicines related information, reassurance and an interest in their care 28 30 37-39 and fulfil a perceived 
gap in their care needs.28  
“I think probably also the psychological effect here that you can talk to somebody you know and 
even if you just get a confirmation of what the doctor has prescribed for you, it’s a big help” (Lay, 
Heart Failure, primary; Lowrie et al., 2014) 
Patients who had not already experienced extended services within CP found it more difficult to identify 
the value of CP for supporting them with their LTCs beyond practical medicines support such as home 
delivery, pill boxes and medication supply.40   Extended self-care was not commonly reported to be an 
area seen to be under the responsibility of the pharmacist. 36 40  
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 “I know that they do offer a lot, but for me, my first port of call would be my doctor” (Lay, LTC 
primary; Ogunabayo et al., 2017) 
Concerns about conflict of interest due to the commercial setting and perceptions of pharmacists as 
“shop keepers” could influence the level of trust patients have in the advice they are provided by CPs 
and their perceptions of their role.37  
“I’m just not sure I’m happy about it at all. ... It’s just at the back of your mind, …, you wonder 
about the drugs companies and all that, and all those promotions in the shop ... is it the kind of 
place they should be doing this kind of thing?” (Lay, CVD, secondary; Bissell et al., 2008) 
 
Construct 2 – Relationships, collaborations and integration 
Pharmacist and other health professional perspectives 
Inter-professional relationships and collaboration can both influence, and be influenced by, perceptions 
of the role of CP, its value in supporting the care of people with LTCs and the implementation of new 
services.  Across studies, there were commonly reported beliefs that the role of CP in supporting 
patients with LTCs was restricted by the lack of integration with wider healthcare teams 33 41 and limited 
access to medical records.36  Traditional views of medical hierarchies which see the CP role as 
subordinate to that of the GP could impede inter-professional collaboration and communication,28 41 
result in concerns about perceived duplication of resources and boundary encroachment28 29 42 and in, 
some cases, a sense of anxiety about engaging with GPs.  
“It depends on the relationship you’ve got with the doctors and if you’re quite happy to speak to 
the doctors yourself.. but if you feel a bit you know how will the doctor take this, they might 
shout at me down the phone or tell me to mind my own business” (CP, Heart Failure, primary; 
Lowrie et al., 2014) 
CPs reported variation in how services, such as NMS, influenced the levels of engagement and 
collaborative working with GPs and nurses in primary care. There was a perception amongst CPs that 
there is a lack of GP awareness and interest in the NMS35 and MURs42 and that they place little value on 
MUR reports. 32 A lack of integration between CP services and existing primary care services was seen to 
limit the support and treatment provided,36 impede implementation and result in confusion for the 
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patient.29  For some CPs, however, a degree of duplication was accepted and conceptualized as evidence 
of valuable reinforcement and integrated care.28  These beliefs may have been specific to the service 
provided within the context of this particular study, which included integrated referral pathways for 
heart failure.   
“it takes a good few times whether it’s their GP or nurse or pharmacist.. it takes .. everybody all 
reinforcing the same thing if they are going to be able to manage their own medicines (CP, heart 
failure, primary; Lowrie et al., 2014) 
GPs were reported to be generally supportive of NMS in principle, but were unclear about its 
implications on boundaries and relationships with CPs and perceived that NMS has little effect on GP/CP 
collaborations.29  Positive examples of collaborative working were however reported in cases where 
there were existing good relationships. 34   Beliefs that the delivery of CP services could damage existing 
positive relationships were also apparent, particularly in cases where there was a perceived lack of 
agreement about their purpose, value and nature.42     
“relationships are excellent [with GPs], no problems at all which is another reason for not getting 
too involved in MURS.  The people that seem to have done them have rather upset their GPs” 
(CP, MUR, primary; Bradley et al., 2008) 
There was little evidence in relation to communication and collaboration with specialist nurses and 
secondary care teams, although similar concerns relating to boundary encroachment seem to exist29.  
Developing these collaborations may be challenging, but was perceived to offer advantages when 
supporting people with LTCs. 43  
Lay perspectives 
Traditional medical hierarchies and views in relation to the authority of the GP over CPs were reported 
to influence lay perceptions on the potential benefits of CP services37 and subsequent engagement. 39  
“I would go and see the doctor, I wouldn’t ask these [CP]... only because in ranking that’s what 
he’s [dr] there for” (Lay, NMS, primary; Latif et al., 2013) 
Patients with good relationships with their GPs did not want these to be put at risk by allowing changes 
to their treatment that the GP had not endorsed  38 39  and patient trust in CP services was greater if 
there had been referral or validation by a GP 38 or other usual healthcare provider. 28  
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 “If the pharmacist just took it on himself I wouldn’t be happy, but I would think if the doctor said 
go and see the pharmacist to discuss it, that would be good” (Lay, diabetes, primary; Twigg et 
al., 2013) 
However, the role of CPs in endorsing GP help-seeking was also valued 28 and CP services were more 
highly regarded when relationships with GPs were poor, access to other services difficult and 
satisfaction with other healthcare services was low. 40   
 CP was seen to occupy an isolated and subordinate position rather than one that is fully integrated with 
the rest of the primary care team.39  This conflicted with patients’ wish for care that is “joined up” i.e. 
not isolated or duplicated and based on knowledge about their medical history and condition. 38  Some 
patients struggled to identify the value and purpose of CP services in supporting their conditions in 
addition to their existing healthcare and wider support networks.  30 38 40  
“Community pharmacists are perceived as relatively marginal to the set of practices, repertoires 
or networks which patients draw on when managing treatments for chronic disease” (Lay, CVD, 
secondary; Bissell et al., 2008) 
Engagement and satisfaction with CP services were also shaped by lay beliefs about the pharmacist 
encounter,  28  traditionally based on patients approaching the pharmacist for advice rather than the 
pharmacist proactively engaging patients in services.32  Deviations from the established interaction 
paradigm were not expected, nor always welcomed.38 39   Lack of clarity and expectations over the 
purpose of services could result in disengagement 31 32  30 and motivation to engage with MURs were 
described by some patients as being for the benefit of pharmacists rather than themselves. 38 39  
“Although  I’m up to speed and  informed with what’s happening with myself, I felt that I was 
happy to do the interview for the benefit of the pharmacist” (Lay, NMS, primary; Latif et al., 
2013) 
Familiarity with individual CPs and repeated contact was important for patients with LTCs in building 
trust and establishing relationships required for supporting their needs 28 38  and for engaging with 
MURs.30 38 39  
 “The relationship part of it is very important, it’s the trust got to build, you can’t just have the 
locum pharmacist coming in and you know he knows nothing about you, you build that 
relationship before you put trust in them” (Lay, Diabetes, primary; Twigg et al., 2013) 
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Interactions with CPs were defined by patients in relation to the ways in which they differed from those 
with other HPs, in particular the GP.    These differences could offer a range of benefits, including: 
patients reporting they could discuss issues they had not been able to with their GP30 37 38;  that the time 
available to discuss their treatment and concerns was valued 28 30 34 37 39;  that CPs were more 
approachable,  “friendly”,  accessible  and more helpful 28 30 33 37 38;  and that repeated consultations with 
CPs can help to empower patients to discuss their conditions and symptoms with their doctors. 28  
“I think it [repeated consultations associated with heart failure service] brings you a lot closer 
you know well I mean the doctors they’re fine, but somehow or another you can’t talk to them 
the same as you can to the pharmacist” (Lay, Heart failure, Primary; Lowrie et al., 2014) 
These descriptions are difficult to reconcile with conflicting findings that although many pharmacists 
endorsed a patient-centred approach 13 based on mutual decision making, 30 actual interactions tended 
to be pharmacist-led, didactic, paternalistic and framed as a monitoring exercise. 31 33 39  This type of 
approach results in patients with extensive disease experience having little scope to challenge the 
pharmacist 31 32  or for their potential expertise to be recognised.  The way in which services such as the 
NMS were framed were reported to encourage pharmacist-led interactions characterized by 
expectations of admissions of non-adherence 31 38  and based on assumptions and stereotypes of 
patients that need “educating” about their medicines.   
“…the pharmacist was explicitly ‘monitoring’ patient behaviours in terms of their understanding 
and use of medicines. Integral to this was an expectation that the patient should admit to ‘non-
adherence’... , this was often framed with some sense of morality, where being adherent is 
‘good’ and being non-adherent ‘bad’. (Lay and HP, NMS, Secondary, Waring et al., 2016) 
Variations in interactions and relationships may occur as a result of differences in pharmacist 
experience, communication and interpersonal skills, understanding of the purpose of services 29 31 and 
stereotypes about patient need. 13 38   
Construct 3 – Socio-cultural, political and commercial drivers and restraints 
In the UK, changes to the role of CP specifically in relation to LTC support have been mainly policy and 
service driven, with the option provided to participate in nationally commissioned services such as NMS, 
CMS, and MURs provided certain requirements are met. 13 29 31   Service delivery has required adaptation 
to new and extended roles and responsibilities, resulting in changes to both lay and professional 
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perceptions of the CP role and its profile. 29 31 34    It has been proposed that these changes are resulting 
in an extension of the “pharmacy gaze” by allowing pharmacists increasing focus on the health and 
lifestyle issues and the wider “life-world” of patients and that this has been instrumental in shaping 
perceptions of where the boundaries of roles and responsibilities of CP towards patients should lie. 31  
Changes in pharmacists’ identities and roles in supporting people with LTCs are reported to be driven by 
corporate and policy visions and priorities for the modernisation of primary care. 31  
“...NMS as a politically-driven strategy for managing demand for GP services and in concert an 
opportunity for professional and business development for pharmacists, eg where the NMS is 
seen to attract additional funding.  This rationality addresses wider socio-economic priorities and 
sees a convergence of policymakers’ and the corporate interests creating a coercive influence not 
only on patients’ but also on pharmacists’ practices” (Lay and HP, NMS, secondary; Waring et al., 
2016) 
Increasingly competitive retail pharmacy environments have meant that organisational pressures to 
engage with MURs differ in nature according to the pharmacy type and organisation size. 13 32 42 Some 
accounts suggested that engagement with MURs in particular were often driven by “top down” pressure 
and financial incentives based on a quantity rather than quality-led approach.32 42 This can challenge 
professional autonomy and adaptation 32 and may be incongruent with perceptions of and identification 
with a professional patient-centred driven role.  
“The way I feel about being forced into doing MURs, you’re just running through the motions, 
they [patients] don’t have any real issues… and that undermines the service, as far as I’m 
concerned (CP, MUR, Primary: McDonald et al., 2010) 
Extending support for the care of patients with LTCs outwith currently funded services was reported to 
be unlikely to occur without a change in the way pharmacy is incentivized to provide these services. 13 41  
Changing the way UK pharmacists are remunerated was suggested as a potential way to increase the 
provision of lifestyle advice,13  enable role extension in LTC management and integration with the wider 
care team32 33 38 and change the priorities placed on dispensing.33   Current commissioning arrangements 
were reported to be resulting in regional variation in the availability of services to support people with 
LTCs. 36 
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“we do not have a commissioned service where we can do medicines use reviews at the patient’s 
home.  However, my colleagues in the neighbouring [area] do have it.. and it’s shown to be a 
valuable service (HP, dementia, primary; Maidment et al., 2017) 
Other socio-cultural influences included beliefs and expectations in relation to the busy commercial 
setting of the pharmacy, particularly if patients were uncertain about the terms under which they could 
approach pharmacists for advice. This may influence, for example, restricting the time and opportunity 
pharmacists have for interacting with patients, 33 the visibility of pharmacists, 38 40 patient expectations 
and perceptions about pharmacy “services”, how long patients are prepared to wait, 13 their likelihood 
of approaching the pharmacist for advice, and whether they perceived that the environment was 
conducive to talking about private medical matters. 30 38   In the UK, there are nationally specified 
standards on patient consultation areas that pharmacies are required to fulfil in order to provide MUR 
services.  Findings from one study highlighted that the availability of private consultation rooms within 
the pharmacy space is not necessarily equated with perceptions of, and interactions associated with, a 
traditional “clinical” environment. 38  
Construct 4 – Operationalisation of services and LTC support 
Finally, lay and health professionals’ understanding of and engagement with new CP services for people 
with LTCs can also be influenced by the way in which services are operationalised.  The need to 
incorporate extended roles and services within busy workloads and the variation in knowledge, 
communication and interpersonal skills of CPs can result in threats to the fidelity to service 
specifications,36  the fulfilment of policy aims39 and confidence in delivery. 28  Some of  the main 
perceived barriers to the implementation of existing and potential services to support people with LTCs 
were restricted capacity to integrate services into daily routines due primarily to pressures on staffing 
and time13 39 41 42  and the commercial need to prioritise services and activities that generate revenue, 
such as dispensing, over activities such as self-care support, and collaborative care planning. 32 33 38   The 
organisational, administrative and remuneration processes of new services were perceived to cause 
additional burdens when capacity is restricted. 34 39  
“It’s difficult to be able to get the time to play more of a role in terms of long-term conditions” 
(CP, LTC, primary; Ogunbayo et al., 2015) 
There were differences in the reported motivation and ability to manage these barriers across different 
types of pharmacy organisations32 42 and to integrate services into daily routines,29  although this was 
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easier when there was more than one pharmacist or a larger support team in place. 29 33   The status of 
the employer is reported to influence the emphasis placed on relationships with patients 13 and relations 
with GPs were felt to be more likely for pharmacies co-located with GP surgeries.35   
“the main diﬀerence [between the Independent workplaces and other pharmacies] is having a 
little talk with them about their medication . .oﬀer extra advice to them so they feel like 
somebody actually cares .” (CP, CVD, primary: Morton et al., 2015) 
The implementation of CP services was reported to be associated with complex logistical, co-ordination 
and communication issues across organisations.   
“It’s difficult when there’s so many people involved in the care of one patient.  There are us and 
the heart failure nurses, GPs and the primary care pharmacists. To coordinate all that and to get 
everybody saying the same thing, that’s definitely.. not easy” (CP, Heart failure, primary; Lowrie 
et al., 2014) 
Standardized formats of service specifications were seen to help support pharmacists in the provision of 
lifestyle advice and behaviour change techniques and increase confidence in delivery. 28 33  The delivery 
of NMS was described as at times being more pharmacist-dominated than intended, 29 although 
“routinisation” did not necessarily result in formulaic interactions 32 and modifications to NMS questions 
were reported to allow a more flexible and patient-friendly approach. 31  
The use of technology, such as telehealth, internet and mobile application technology, to facilitate self-
care was supported in principle, but not currently widely utilised and the availability of technology and 
technological expertise varied. 29 32 33   CPs perceived that this may be particularly valuable when working 
with younger age groups 43 and in supporting medication adherence for people with LTCs more widely. 
33  
Wider public awareness campaigns and publicity are commonly suggested requirements to increase 
understanding and uptake of CP services and patient engagement with CP.   National services such as 
MUR and NMS in particular were perceived to require a range of proactive engagement approaches to 
encourage patients to take part, due to a lack of public awareness and understanding of the services 
being offered. 29 32 34  
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“I think the main thing is advertising the service, we have leaflets and things like that but 
somehow the service still doesn’t appeal.. there will be a percentage of people who will see 
pharmacists as just dispensers” (CP, NMS, primary; Latif et al., 2016) 
CPs were reported to be more confident in their traditional dispensing and medicines “expert” and 
“educator” roles and less so in relation to wider self-care support and collaborative care planning.   It 
has been suggested that there is therefore a need for further training, particularly to improve 
understanding of the nature of treatment for specific conditions (such as dementia or coronary vascular 
disease), specific patient groups (such as young people), 13 36 43  and for addressing concerns in relation 
to complex needs, co-morbidities and skills in behaviour change. 28  
DISCUSSION  
Analysis of qualitative findings from the papers included within this study suggests that the role of CP in 
facilitating the care of people with LTCs is complex, at times ambiguous and continually evolving in 
response to drivers from within and external to the profession.  Variation in understandings and beliefs 
about the CP role and services exists both within and across stakeholder groups.  Four key overarching 
constructs were identified: conceptualisation, disruption and adaptation; relationships, collaboration 
and integration; socio-cultural, political and commercial drivers and restraints; and operationalisation of 
services and LTC support.  A theoretical framework is proposed which illustrates the overlap and 
relationships between these constructs and the influence of individual level factors within each of the 
stakeholder groups. This framework highlights how attitudes towards the role of the community 
pharmacist can both influence and be influenced by behaviour (i.e. service development, 
implementation, delivery and utilisation) and the socio-cultural environment in a dynamic way that is 
reflective of Bandura’s behavioural theory of reciprocal determinism. 44   It is therefore important to 
acknowledge influences within and beyond the CP setting and the varying perspectives between 
stakeholder groups when developing and evaluating future services and the role of CP in supporting 
LTCs more widely.  Failure to do so may result in a lack of patient or health professional engagement, 
sub-optimal improvement of health outcomes and/or CP not fulfilling its potential contribution to the 
demands on the wider health care system.  The proposed framework can provide a structure to help 
facilitate the consideration of key perspectives, issues and drivers to role and service development and 
implementation.  It can also aid our understanding of the contexts and mechanisms to be assessed when 
evaluating new initiatives, highlight knowledge gaps and shape future research priorities and 
approaches. 
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Findings suggest that over the last decade, the conceptualisation of the role of CP has been 
characterised by disruption to the “traditional dispensing role” and adaptation to change.  Despite 
reports of positive attitudes, a culture amenable to change and a general willingness of CPs to support 
patients with LTCs, there remains an underlying ambiguity about the existing and potential value of the 
role of CP in this area, particularly from the perspective of patients.  As the proposed framework 
illustrates, role development and conceptualisation is driven by conflicting and evolving demands from 
the wider socio-political, economic and cultural environment; interaction with patients and the wider 
health care system; and within CP itself.  Variation in perceptions, beliefs, expectations and behaviour 
(such as public engagement with extended CP services or pharmacist willingness to deliver them) can 
result from an interaction between this dynamic overarching process and a range of factors that exist at 
the individual level.  For example, pharmacy contracts and payment structures can have an important 
influence on perceptions of the CP role directly via the initiation and implementation of new services, 
but also indirectly via experience of service delivery.    Other research studies using survey methods 
have also found that experience of extended CP services influences subsequent interactions with the 
pharmacist and plays a significant role in developing and changing lay perceptions of the value of CP in 
supporting patients with their LTCs.20 21   Attitudes towards CP do not necessarily relate to behaviour, 21  
however, and service utilisation will depend not only on availability, awareness and satisfaction with CP 
services, but also on a range of other individual influences.  These could include patients’ illness beliefs 
and experience, existing self-management and coping skills, individual illness trajectories, treatment 
response and the availability and use of other support networks and services.45   
 
From a pharmacist perspective, and as highlighted by research on the NMS in England,31 the delivery of 
commissioned extended services allows an increasing focus on the wider “life-world” of patients which 
can in turn influence pharmacists’ perceptions of their role.  Although the value of adapting to a more 
patient-centered approach in supporting LTCs was often recognised, evidence suggests this is not always 
reflected in practice. The emphasis on the bi-directional relationships between the constructs within the 
proposed framework can help account for the seemingly conflicting finding that conceptualisation of the 
role can also be instrumental to the way in which services are operationalized; albeit shaped by other 
individual level and wider restraints and drivers.   A previous study on the professional identity of 
pharmacists identified a range of elements associated with the role.46  Although the  “scientist” element 
was found to be the strongest,  close association with a range of other elements was seen to  reflect  
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flexibility and amenability to change.46    Findings from the papers included in this synthesis suggest that, 
although perceptions of the role are continually evolving, the role of “educator/informer”, specifically in 
relation to medicines, remains a commonly dominant representation. This tends to be associated with a 
more didactic and paternalistic approach to the delivery of services supporting adherence and self-care 
and, in many contexts, can be misaligned with the principles of more patient-centered models of care 
for LTCs and theoretical approaches to behaviour change. 47 48  A recent systematic review suggests that 
this issue is not only restricted to pharmacists but has also been identified within other healthcare 
professions. 49  Findings from a study evaluating  a new pharmacy personalized care plan service for 
patients with LTCs,  which was published after the literature review for this synthesis was completed, 
demonstrate that consultation skills training can help support pharmacists adopt a more patient-
centered approach. 50   Uncertainty remained, however, over whether this approach was consistent with 
the CP professional role and pharmacists reported a lack of confidence in their ability to support the 
wide range of different health goals identified by patients.  In line with findings from the papers included 
within this synthesis, adequate resources, capacity and the need for integration with the healthcare 
system were highlighted as key elements for successful service provision, despite positive attitudes 
towards the service.50    
 
The need for quality integrated care is recognized more widely for supporting people with LTCs and new 
integrated models of care are currently being promoted and evaluated within the UK.1 2 4 51 The role of 
the pharmacist was found to be conceptualized by patients and carers in relation to those of other 
healthcare providers supporting their LTCs, in particular the GP.  Integration with existing support 
structures provided by health professionals and lay or peer networks and concerns about potential 
duplication, traditional medical hierarchies and the commercial and healthcare policy environment in 
which CP is situated are therefore essential considerations.  Successful inter-professional collaboration, 
however, depends on CP having a clearly delineated, recognized and valued contribution and place 
within the self-care support system in order to effectively engage with the wider multidisciplinary 
teams33 and patients.  There is longstanding literature on the influences on and impact of relationships 
between GPs and community pharmacists, 52-55 professional boundaries in relation to prescribing and 
clinical autonomy, 52,56 responsibilities, 16 power relationships and medical hierarchies. 31  Overcoming 
inter-professional barriers to collaboration and communication is important to ensure services provided 
within CP meet patient need and that new service configurations are successfully and cost-effectively 
disseminated, implemented and utilized.56   A key challenge is ensuring confidence and trust in the CP 
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services by GPs and other healthcare providers as well as members of the public. 57 The need for  GPs to 
understand and be more aware of CP expertise for successful collaborations to take place has been 
highlighted by others,58 however, this study also highlights the importance of  specifically distinguishing 
between GP beliefs about the value of specific contracted services being offered within CP (such as 
NMS, CMS, and MURs), GPs  concerns about potential duplication, and their awareness and recognition 
of the expertise of the CP profession, the latter of which seems to be consistently viewed more 
positively.     Potential overlap between services should therefore be explicitly addressed, ensuring that 
the contribution of CP is perceived and delivered as valued reinforcement with clear agreed boundaries 
of responsibility rather than duplication.  
 
Strengths and weaknesses 
The main strength of this meta-ethnography is that analysis was based on studies that focused on a 
range of LTCs, services and participants, all covering a wide geographical area within the UK.   By their 
nature, published qualitative research findings include a representation of the authors’ 
conceptualisations of their data based on themes or concepts perceived to be of most importance to 
them.   Study findings are context specific and their value lies in the rich in-depth understandings and 
interpretations specific to each.  Methodological arguments have been presented against the synthesis 
of qualitative research 25, however, Britten, et al. 22 suggest that “interpretative methods such as meta-
ethnography can provide a means to generalise findings that “do not supplant the detailed findings of 
individual studies, but add to them” and that “transferability of shared meanings and generative 
mechanisms is possible and indeed useful”.  This meta-ethnography cannot, however, account for data 
that was not included within the published version of the findings.   
 
A range of different qualitative methods were used within and across studies, including, focus groups, 
face to face interviews, telephone interviews and ethnographic observation.  This can help to strengthen 
confidence in the findings by providing an opportunity for method triangulation. The potential for bias 
and the impact of “stigma” and social desirability on individual accounts should be acknowledged, as all 
the findings relate to perceptions and “public” accounts of beliefs and self-care behaviours.  Although a 
range of sampling methods were employed across studies, it is also likely that there may have been 
some biases in sampling, with recruitment to both the services being evaluated, and the studies 
evaluating them, biased to those who may have more positive views towards the services, CP or 
different support needs.   Reliability and transferability of our findings depend in part on the reliability 
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and quality of the research synthesised and is limited by the data that was available for inclusion.  
Further research would be needed to ascertain the extent to which the findings and conceptual 
framework presented are transferable to other settings and healthcare systems.  
 
Current healthcare practice, policy and the political landscape is changing rapidly.  Although studies 
included were published within the last 10 years to reflect more recent developments, the data on 
which these papers were based were collected between 2002 and 2014.  It was not possible to analyse 
findings based on more recent changes in attitudes and perceptions or on recent service developments 
within community pharmaceutical practice.    
 
Only one paper included the perceptions of carers and specialist nurses and two the perspectives of GPs, 
despite the key role they play in supporting patients with a range of LTCs and the importance of the 
relationship between the CP and the GP featuring strongly in many of the accounts.   Research on 
methods or interventions to help improve collaboration and interdisciplinary working between CP and 
GPs has been suggested41 and this would also apply to other healthcare providers.  Further research is 
also needed to ascertain the experiences, opinions and beliefs of a wider range of patients living with 
LTCs, in particular those who are non-service (NMS, MUR or CMS) users 30 or from pharmacies who do 
not wish to offer such services. 29    
 
Further evidence on the potential value of integration with LTC support networks and the use of 
technologies in self-care support for people with LTCs within CP could also be valuable for developing 
improved patient-centred services. 33  Research on the implementation, diﬀusion or translation of 
innovations into healthcare settings within the CP setting is reported to be largely under-explored. 29 
Existing theoretical work and conceptual models on the diffusion, dissemination and implementation of 
innovation in health service delivery 59, 60 may be valuable in this regard, particularly in light of a policy 
focus on new integrated models of care to support personalized care.1 2 50  
  
CONCLUSIONS 
The role of CP in the UK is varied, complex, at times ambiguous and continually evolving in response to 
drivers from both within and external to the profession.  Despite a certain level of optimism for an 
extended professional role in CP to help to facilitate the care of people with LTCs, there is variation 
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within and across CP, lay and other health professional perspectives on how this might meet the needs 
of patients and contribute to reducing demand on the healthcare system.   
The proposed conceptual framework presented in this paper helps to explain the dynamic processes and 
socio-cultural influences involved in how the role of CP is perceived.  It outlines the range of influences 
within and beyond the CP setting that may benefit from consideration when extending the role of CP 
and implementing new models of care for people with LTCs.   
Effective service implementation and delivery, successful engagement with patients and positive health 
outcomes are more likely if the LTC support provided is patient-centred, compatible with the perceived 
and actual capacity and skills available within CP and fully integrated within existing healthcare and lay 
support networks.  One challenge in particular is the delineation of the role of the community 
pharmacist within the wider NHS healthcare system.  This is complicated by unclear professional 
boundaries, traditional perceptions of medical hierarchies and the perceived potential for conflict from 
commercial and other external pressures.  Integration and potential overlap with other services should 
therefore be explicitly addressed, ensuring that the latter is perceived and delivered as valuable 
reinforcement rather than duplication.   
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Table 1 – Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
Population:  
Community pharmacists; patients and carers 
either diagnosed with, or caring for, a person with 
a long-term condition; health professionals 
 
Study aims include the identification of: health 
professional and lay perspectives of the existing or 
potential role of community pharmacists or 
community pharmacy services in facilitating care 
for people with long-term conditions, including 
lifestyle and self-management.  
Study aims focus on: primary prevention, screening 
and/or other public health issues; education 
research; adherence behaviour; medicines use or 
dispensing; acute conditions or settings; inter-
professional barriers; quality of life; and self-care or 
self-management support not specific to community 
pharmacy. 
Language: English  
Country: UK  
Year limits: 2007-2017  
Type of Publication: Peer reviewed Non-peer reviewed or grey literature 
Study type: Qualitative methods including 
interviews, focus groups or consensus methods or 
mixed methods paper with a distinct qualitative 
component  
Open-ended questionnaire data or quantitative 
methods 
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Table 2 – Summary of papers including health professional perspectives in relation to the role of CP in facilitating care for long-term 
conditions in the UK.  
Author Lucas and 
Blenkinsopp (2015) 
Latif et al. (2016) Waring et al. (2016) Wells et al. (2014) Ogunbayo et al. (2015) Morton et al. (2015) 
LTC or 
Community 
Pharmacy 
Service 
NMS NMS NMS NMS (pre-implementation) General views on providing self-
care support for patients with LTCs 
Lifestyle advice in CVD 
Participants CPs CPs and GPs CPs and patients CPs and Superintendent Pharmacists CPs CPs 
Year data 
collected 
2012 2012-2013 2012-2013 2011 2013 unknown 
Methods Telephone interviews Observation and interviews Ethnographic observation and 
interviews  
Focus groups and interviews Interviews  Interviews (face to face and 
telephone) 
Study Aims To explore CP experiences 
and perceptions of NMS 
within one area of the UK. 
To investigate the NMS 
implementation process how 
the NMS is being translated 
into the CP practice setting 
and if and how the NMS 
service and pharmacy practice 
are transformed.   
To develop a Foucauldian 
analysis of the changing forms of 
power brought about by 
extended CP roles with reference 
to the introduction of the NMS.  
To explore the views of pharms and 
superintendent pharms before 
implementation of NMS to identify 
facilitators or barriers to NMS 
implementation. 
To explore CPs contribution to self-
care support in the management of 
LTCs. 
To explore CPs experiences and 
perceptions of providing lifestyle 
advice for patients with CVD. 
Sampling and 
recruitment 
Purposive sampling 
(deprivation, pharmacy 
types) used to identify 14 
interviews. 
Ethnographic observation; 
workplace interviews with 47 
CPs and 11 GPs. Pharmacies 
purposively sampled from 
those included within larger 
RCT/evaluation of the service. 
CPs purposively sampled by 
pharmacy type, geographical 
area and area of social 
deprivation.  
Purposive sampling of patients 
accounting for age gender 
ethnicity and health condition 
for ethnographic observation 
and interviews with 27 CPs. 
15 pharmacists over 4 focus groups 
and 5 superintendent pharmacist 
interviews. Purposively sampled by 
employee and locum pharmacist roles 
and by pharmacy type. 
Purposive maximal variation 
sampling (pharmacy types, location, 
pharmacist demographics) and 
snowballing. 12 CPs from England 
and 12 from Scotland recruited via 
LPCs, random direct contact.   
15 CP interviews recruited from 
advertising at a meeting for local 
pharmacists and contacting a 
randomly selected list of CPs and 
snowballing.  Purposively sampled 
various pharmacy types and 
pharmacist experiences.  
Analytic 
approach  
Thematic analysis Thematic analysis informed by 
Damschroders’ consolidated 
framework for 
implementation research 
Interpretative grounded 
approach 
Thematic analysis Interpretative Phenomenological 
Analysis 
Framework Approach 
Location England (West Yorkshire) England (London, Midlands, 
South Yorkshire) 
England (London, Midlands,  
South Yorkshire)  
England (Nottingham) England (Manchester) and Scotland 
(Tayside, Glasgow and Clyde) 
England (East and West midlands) 
Key Findings Pharmacists gave mixed 
responses to 
operationalisation ranging 
from positive opportunities 
for improving adherence and 
enhances of practice to 
difficulties in its 
administration.  Pharmacists 
generally welcomed 
opportunities to utilise their 
professional expertise to 
achieve better patient 
engagement and for the 
development of pharmacy 
practice.  Different levels of 
collaborative working with 
GPs and nurses were 
reported.   NMS was an 
opportunity for collaboration 
however others reported a 
lack of feedback and 
recognition of their role.  
Perceived need for better 
publicity.   
NMS workload implemented 
and absorbed into daily 
routines alongside existing 
responsibilities with no extra 
resources.  Pharmacists 
adapted NMS to facilitate 
delivery according to their 
understanding of what they 
believe should be achieved.  
Despite pharmacists holding 
positive views about the value 
of the NMS, not all were 
convinced of its perceived 
benefits and necessity.  GPs 
were generally supportive of 
NMS, but were unaware of 
the service or potential 
benefits.  Poorly developed 
GP-CP relationships impeded 
implementation.  Community 
pharmacy workflow, 
infrastructure and public and 
professional relationships all 
affect NMS implementation.   
Patient and pharmacists 
subjectivities are transformed as 
pharmacists seek to survey 
medicine use diagnose non-
adherence to prescribed 
medicines and provide education 
to promote behaviour change.  
Extended roles in medicines 
management and patient 
education expand the 
pharmacist gaze to further 
aspects of patient health and 
lifestyle and more significantly 
establish a form of pastoral 
power as pharmacists become 
responsible for shaping patients 
self-regulating subjectivities.  
Pharmacists are themselves 
enrolled within a new governing 
regime where their identities are 
conditioned by corporate and 
policy rationalities for the 
modernisation of primary care.  
Pharmacists and SPs were positive 
about NMS and identified potential 
benefits for patients and pharmacy 
profession.  Awareness of service was 
high, however there was confusion 
over aims and overlap with MURs.  
Pharmacists’ positive attitudes, 
similarity to current practice and the 
self-accreditation procedure as 
potential facilitators to service 
implementation.  Barriers include a 
perceived lack of interest and 
awareness by GPs of the service and 
the payment structure.   
Pharmacists’ views of self-care 
support did not reflect their 
conceptual understanding of self-
care and was described as providing 
information and advice rather than 
active support.  Operationalization 
was found to be medicines focused 
opportunistic and dependent on the 
services they provided rather than 
being patient- centred and 
proactive.  Barriers were described 
as priority of dispensing, structure 
of pharmacy contract, lack of 
incentives and patient expectations 
and lack of awareness of 
community pharmacy's role. 
Pharmacists categorise patients 
according to their perceptions of 
the patients' ability to benefit from 
advice.  Many barriers to providing 
lifestyle advice identified mainly 
underpinned by professional 
identity and role conflict.    
Confidence to provide lifestyle 
advice varied with pharmacists 
more comfortable when this was in 
conjunction with conversations 
about medicines.  Some felt this 
was an integral part of their role 
whilst others questioned whether 
pharmacists should do this at all, 
particularly if not remunerated.   
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Table 2 (cont’d) – Summary of papers including health professional perspectives in relation to the role of CP in facilitating care for long-term 
conditions in the UK.  
Author Lowrie et al. (2014) Maidment et al. (2016) Maidment et al. (2017) 
 
 
Gray et al. (2016) Bradley et al. (2008) Macdonald et al. (2010) 
LTC or 
Community 
Pharmacy 
Service 
HF service based on a 
theoretical model of behaviour 
change.  
General views on role of CP in 
limiting antipsychotic use in 
dementia. 
Dementia (views on potential role 
of community pharmacists in self-
care support) 
 
Perceived and actual roles of 
pharmacists in care of young people 
with chronic illness (juvenile arthritis) 
MUR MUR 
Participants CPs and patients CPs  CPs, patients GPs, nurses, social 
care health professionals 
CPS, but also hospital pharmacists, 
rheumatology team  
Mixed CPs and PCOs CPs 
Year data 
collected 
2006 2013 Not stated 2012-2013 2006 2007-2008 
Methods Focus groups and telephone 
interviews 
Focus groups Face to face interviews Mixed methods incorporating 
pharmacist focus groups and 
stakeholder telephone interviews 
Mixed-methods, incorporating 
case study interviews (face to 
face and telephone) 
Interviews (mainly telephone, 
some face to face) 
Study Aims To explore patient and CP views 
of a CP based HF service as part 
of an evaluation of the service.  
To examine the current role of CPs 
with respect to the use of 
antipsychotics in behavioural and 
psychological symptoms of 
dementia (BPSD). 
To describe key challenges in 
relation to medication issues 
experienced by people with 
dementia and their informal carers 
and the potential role of CP. 
To explore the perceived and potential 
roles of pharmacists in the care of 
young people with chronic illness 
though the exemplar of juvenile 
arthritis from the perspectives of UK 
community and hospital pharmacists 
rheumatology, health professionals, 
and health service commissioners. 
Aims of interviews:  to explore 
and elucidate stakeholders' 
views on the approach to and 
experience of the commissioning 
and provision of CP services, with 
a particular focus on MURs.  
 To  use MURs to explore 
changes in professional status in 
English community pharmacy.  
Sampling and 
recruitment 
2 Focus groups with 10 CPs; 
Telephone interviews with 65 
service users sampled from the 
first 200 service users to receive 
the service.  Respondents were 
63% male; 40% from deprived 
areas.  
Purposive and snowball sampling 
recruited via local pharmaceutical 
networks resulted in 22 CPs 
attending 3 focus groups. 
11 carers, 4 people with dementia, 
4 GPs, 5 nurses, 3 social care 
Professionals, 4 CPs) recruited from 
Alzheimer’s Society, Dementia UK, 
GP surgeries, professional networks 
and local dementia support groups. 
Purposive maximum diversity sampling 
recruiting from professional bodies, 
educational organisations and 
advertising. 4 Focus groups and 15 
telephone interviews. 
Purposive sample of 
stakeholders involved in 
commissioning and providing CP 
services, including:1 
commissioner,1 local 
pharmaceutical committee 
representative and 3 CPs for 
each of 10 case study sites.  
Opportunistic snowballing 
sampling 49 CPs. 
Analytic 
approach  
Framework Analysis - 
Normalisation process theory 
used to conceptualise and 
interpret responses 
Thematic analysis Framework Analysis Directed content analysis (middle 
order thematic approach) 
Thematic Analysis Open coding and constant 
comparison  
Location Scotland England England (West Midlands, South, 
Yorkshire  and North East) 
 
England, Scotland and Wales England (various locations) England (North West/Yorkshire 
and Humber)  
Key Findings Pharmacists were confident in 
delivering service and 
highlighted valued aspects 
including the structured 
consultation and repeated 
contacts with patients enabling 
the opportunity to improve self-
care and medicines adherence.  
Discussing co-morbidities other 
than HF and persuading 
patients to modify behaviour 
was challenging. 
Politics and medical hierarchy 
creates communication barriers.  An 
improvement in communication 
between CPs and HPs especially GPs 
must occur in order for CPs to assist 
in limiting the use of antipsychotics 
in people with dementia.  Extra 
training is required for CPs to work 
with patients with dementia.  
Community pharmacists question 
the extent to which they can 
contribute in this area.  Resources 
and remit impact effectiveness of 
CP.   
The process of medication 
management could be improved by 
coordinated and ongoing support 
from health and social care 
professionals focused on the 
informal carer. Medication reviews 
conducted in the home 
environment could be helpful.  
Community pharmacists could have 
an enhanced role but would need 
to work within a more 
multidisciplinary environment 
outside the pharmacy. 
High priority roles for pharmacists 
were developing generic health care 
skills among young people. 
Transferring information effectively 
across care interfaces, building 
trusting relationships with young 
people, helping young people to find 
credible online information, and the 
need to develop specialist expertise.  
Challenges included parent collecting 
prescription refills, and reduced 
opportunities to engage, and 
pharmacist isolation from the wider 
heath care team.  
Organisational pressure within 
multiple pharmacies is driving 
forward MUR activity in some 
primary care organisations. 
There is a lack of communication 
between CPs and GPs.  
Responses to reforms are not 
necessarily in accordance with 
either national policy goals or 
enhancement of professional 
status. Debates about 
professional status and role 
extension have often focused on 
health professions' 
subordination to medicine. This 
paper highlights the importance 
and interplay of other factors 
which help explain the inability 
to capitalise fully on the 
potential contribution to 
professional status, which 
reforms to extend professional 
roles afford. 
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Table 3 - Summary of papers including lay perspectives in relation to the role of CP in facilitating care for long-term conditions in the UK 
Author Lowrie et al. (2014) Twigg et al. (2013) Bissell et al. (2008) Maidment et al. 
(2017) 
Ogunbayo et al. 
(2017) 
Latif et al. (2013) van den Berg and 
Donyai (2014) 
Waring et al. (2016) 
LTC or service Heart Failure  Diabetes   CHD/MUR Dementia Multiple LTCS (Asthma, 
COPD, CVD and diabetes) 
MUR   MUR NMS 
Participants Patients and CPs Patients Patients Patients, Carers, CPs  
GPs, Nurses, Social care 
health Professionals 
Patients Patients  Patients Patients and CPs 
Year data 
collected 
2006 2011 2002-2004 Not stated 2013-2014 2008-2009 2009-2010 2012-2013 
Methods Focus groups and 
telephone interviews 
Focus groups Interviews Face to face interviews Face to face interviews Ethnographic observation and 
interviews 
Observations and 
interviews 
Ethnographic observations and 
interviews  
Aims of Study To explore patient and CP 
views of a CP based HF 
service as part of an 
evaluation of the service.  
To understand the norms 
Type 2 diabetes patients 
when visiting pharmacy 
support staff and the 
pharmacist. 
To describe patients’ 
experiences of a medicines 
management service 
provided by CPs  for people 
with coronary heart 
disease. 
To describe key 
challenges in relation to 
medication issues 
experienced by people 
with dementia and their 
informal carers and the 
potential role of CP. 
To gain deeper insight into 
patients' self-care 
behaviours in relation to 
their use of community 
pharmacy for self-care 
support. 
To describe patients' 
perspectives of the MUR 
service and their 
understanding of the value 
that they derive from it.  
To determine how 
patients perceive and 
evaluate the MUR 
service in order to 
identify satisfaction 
criteria. 
To develop a Foucauldian 
analysis of the changing forms of 
power brought about by 
extended CP roles with reference 
to the introduction of the NMS in 
the English NHS. 
Service details Heart Failure service based 
on a theoretical model of 
behaviour change involving 
repeated consultations.  
Referral pathways 
integrated into health care 
system.  
Not service specific but 
focus groups asking re: 
expectations.  
CP-led medicines 
management service for 
CHD patients (MUR). 
Not service specific but 
views on potential role 
of community 
pharmacists in self-care 
support. 
Not service specific but 
general views on use of 
Community Pharmacy for 
self-care support in LTCs. 
MUR - no information about 
the LTCs of interviewees.   
MUR – no information 
about the LTCs of 
interviewees. 
Part of national evaluation of 
NMS  - range of LTCs. 
Sampling and 
recruitment 
2 Focus groups with 10 
CPs; Telephone interviews 
with 65 service users 
sampled from the first 200 
service users to receive the 
service.  Respondents were 
63% male; 40% from 
deprived areas. Referred 
by GP, specialist or 
specialist pharmacist, 
many of whom had agreed 
to be referred. 
44 patients presenting at a 
pharmacy for T2D 
medication (age range 41-
80 although most more 
elderly) purposively 
sampled based on gender, 
age, number of 
medications prescribed, 
length of time since 
diagnosis. 
49 patients recruited to 
RCT/service via GPs. A 
purposive maximal 
variation sampling 
approach was used.   
11 carers, 4 people with 
dementia, 4 GPs, 5 
nurses, 3 social care 
Professionals and 4 CPs 
recruited from 
Alzheimer’s Society, 
Dementia UK, GP 
surgeries, professional 
networks and local 
dementia support 
groups. 
Convenience sampling of 
15 patients in England and 
9 in Scotland. Recruited to 
study by GPs and 
pharmacies. 
Unstructured ethnographic 
observation of 54 patient-
pharmacist MUR 
consultations.  Convenience 
sample of 34 patient 
interviews. Identified and 
invited by CPs as per usual 
practice.  
7 MUR observations and 
interviews with 
patients.  15 face to face 
interviews with patients 
who had received a 
MUR within last 6 
months. All recruited via 
large multiple pharmacy 
in specific area. 
19 patients purposively sampled 
(age gender, ethnicity and health 
condition) and 27 CPs. 
Analytic 
approach  
Framework Analysis - 
Normalisation process 
theory used to 
conceptualise and 
interpret responses 
Thematic analysis Interpretative analysis Framework Analysis Descriptive 
phenomenology 
Thematic analysis Thematic analysis using 
framework approach 
using Donabedian’s 
structure-process-
outcome approach 
Interpretative grounded 
approach 
Location Scotland England (Norfolk) England  England (West 
Midlands, South, 
Yorkshire  and North 
East) 
England and Scotland England (Midlands) England (Surrey) England (London, Midlands and 
South Yorkshire)  
Key Findings Patients were comfortable 
discussing symptoms and 
medicines with 
pharmacists.  They 
identified pharmacists as 
fulfilling roles that were 
needed but not currently 
addressed.  They reported 
the service helped them to 
enact HF medicines and HF 
self-care management 
strategies.   
Two themes: place of the 
pharmacy in the wider 
primary care team and 
pharmacy as a health care 
destination. Participants 
with T2 diabetes identified 
a role for pharmacists in 
their care linked to their 
perceived expertise on 
medicines.  The extent to 
which they would engage 
with the pharmacists 
depends on the quality of 
the relationship with their 
GP or practice nurse.   
Findings suggest that 
although patients 
cautiously welcomed the 
opportunity to consult with 
a pharmacist about their 
medicines, they had 
reservations about them 
making recommendations 
about treatment, and 
many still regarded the 
doctor as the health 
professional ‘in charge’ of 
their medicines.  
The process of 
medication 
management could be 
improved by 
coordinated and 
ongoing support from 
health and social care 
professionals focused 
on the informal carer 
and medication reviews 
conducted in the home 
environment.  
Community pharmacists 
could have an enhanced 
role but would need to 
work within a more 
multidisciplinary 
environment outside 
the pharmacy.  
Participants’ use of and 
identified need for CP as a 
resource for self-care 
support of LTCs was limited 
and primarily focussed on 
medicine supply.  Low 
awareness and visibility of 
CP potential roles and 
capability.  CP needs to 
rethink how interventions 
are designed and 
marketed; incorporation of 
patients’ perspectives and 
collaboration with others, 
particularly GPs could 
prove beneficial.   
All patients reported feeling 
comfortable speaking with 
the pharmacists who they 
saw as a knowledgeable 
expert on medicines.  They 
appreciated time spent with 
them during consultations.  
MURs provide patients with 
reassurance that they are 
doing the right thing.  Patients 
provided mainly positive but 
ambivalent accounts of the 
purpose of the MUR.    
Evidence that MURs are 
fulfilling their formal policy 
aims and intentions was 
limited. The patient 
perspective needs to be more 
fully considered.  
5 themes linked to 
patient satisfaction 
were identified: 
relationships with HPs; 
attitudes towards HPs; 
Experience of health, 
healthcare and 
medicines; views of the 
service; logistics of the 
services.   
Patient and pharmacists 
subjectivities are transformed as 
pharmacists seek to survey 
medicine use, diagnose non-
adherence to prescribed 
medicines and provide education 
to promote behaviour change.  
Extended roles in medicines 
management and patient 
education expand  the 
pharmacist gaze to further 
aspects of patient health and 
lifestyle and more significantly 
establish a form of pastoral 
power as pharmacists become 
responsible for shaping patients 
self-regulating subjectivities.   
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Table 4 – Development of final key constructs from primary data and secondary concepts 
EXAMPLE 1 - Key Construct 3: Socio-cultural, political and commercial drivers and 
restraints  
 
Examples of Primary data   Examples of Secondary concepts Examples of 
Tertiary concepts 
“[multiples] have got head ofﬁces 
telling them off, ringing them up, 
shouting at them to do MURs and 
come hell and high water they’re 
doing MURs ... Independents on the 
other hand are opting out, burying 
their head in the sand, not doing it, 
seeing it as not part of ... their 
priority.” (PCO representative, Site 
E) HP, MUR (Bradley and al, 2008) 
 
I have to deliver 400 MURs. No 
doubt about it. If I’m short by a 
hundred, then I’ll be in trouble. (ID 
23, salaried, multiple) HP, MUR  
(McDonald et al., 2010) 
 
“..if you are stopping a heart attack 
then they’re not going to be taking 
any medicines and that’s ultimately 
putting yourself out of business so 
it’s not in your interests to keep 
people healthy as a pharmacist at 
the moment . what other profession 
does something to stop their future 
payments?” IndepCP1(23yrs). HP, 
CVD (Morton et al., 2015) 
The interview ﬁndings suggest an emerging split in the way multiple and independent 
pharmacies operationalised MURs.  Strong concerns were expressed by interviewees at 
ﬁve of the case study sites that multiple pharmacies were pressurizing employee 
pharmacists to maximise MUR activity.  …  Some interviewees stated that MURs were 
time consuming, particularly independent pharmacists, several of whom had undertaken 
the accreditation but found it difﬁcult to ﬁt MURs into their daily activity. (Bradley and al, 
2008) 
 
Our data suggest that the formalisation and incentivisation of MURs is leading to a 
distortion in the provision of advice to patients, with pharmacists under pressure to offer 
MURs to patients, based on the commercial needs of the pharmacy rather than the 
patient. Furthermore, the clear link between the MUR and ﬁnancial rewards makes some 
pharmacists uncomfortable, and may detract from the potential of MURs to raise 
professional status, by highlighting commercial, as opposed to patient, interests. 
(McDonald et al., 2010) 
 
Many pharmacists described balancing multiple roles in a time limited environment which 
placed them under pressure to meet targets and provide a quick service. This appeared to 
leave some pharmacists resigned to not being able to oﬀer patients advice. (Morton et al., 
2015) 
Commercial and 
organisational pressures 
influence engagement and 
interaction with patients 
“. ,you’re providing the [lifestyle] 
advice . erm and you’re getting no 
monetary reward for it . so most 
pharmacists will think oh I can’t be 
bothered to be giving that advice, 
when there’s no value to it for me”. 
MultiCP6(1yr) HP, CVD (Morton et 
al., 2015) 
 
“If you were reimbursed more 
appropriately for patients who take 
a lot more time to be dealt with. 
(NE4)” HP, Dementia (Maidment et 
al., 2016) 
A ﬁnal more implicit rationality sees the NMS as a politically-driven strategy for managing 
demand for GP services, and in concert, an opportunity for professional and business 
development for pharmacists, e.g. where NMS patients attract additional funding. This 
rationality addresses wider socio-economic priorities, and sees a convergence of 
policymakers’ and the corporate interests creating a coercive inﬂuence not only on 
patients', but also on pharmacists' practices. (Waring et al., 2016) 
 
UK pharmacists’ payment structure, that remunerates pharmacists directly per 
prescription item dispensed but provides no remuneration for lifestyle advice may 
reinforce beliefs that providing lifestyle advice is not an important or valued part of the 
pharmacists’ professional role. .. The pharmacist describes an inherent conﬂict between 
their role as a health professional with a responsibility to promote health through giving 
patients lifestyle advice, and their business employee role which focuses on ﬁnancial 
return, which giving lifestyle advice does not currently provide. (Morton et al., 2015) 
 
The idea of introducing another responsibility into this role raises challenges, not least 
with respect to community pharmacists’ professional identity, competency and stretched 
resources. Furthermore, in the absence of an incentive for community pharmacists to 
take on additional work, it is unlikely that this role will develop”. (Maidment et al., 2016) 
 
Changes in the role of the 
pharmacist and service 
implementation are mainly 
driven by policy and 
contract changes 
‘This is building on the MUR’s service 
that already exists, so.the 
expectation will be that this is the 
sort of thing you do.’ P9 (Female, 
large multiple, age 41–50 yrs) HP, 
MUR (Wells et al., 2014) 
This cultural change within the profession [introduction of MURs] was cited as the main 
reason for the slow uptake of MURs with the attitudes of individual pharmacists 
determining the speed of service implementation. Participants thought that the 
[resulting] change in how pharmacists perceived their job role would enable quicker 
uptake of any new service introduced. (Wells et al., 2014) 
 
Viewing all of these features of both the pharmacy and pharmacist, together, highlights 
many changes the community pharmacist and the wider healthcare team will need to 
make if patients with diabetes, or others with chronic conditions, are going to conﬁdently 
engage eﬀectively with new pharmacy services and see the pharmacist as a credible 
healthcare professional. This may involve changing the perception of the pharmacist by 
patients but also, and possibly more importantly, changing the way pharmacists work and 
are paid by the NHS. (Twigg et al., 2013) 
Wider socio-cultural 
influences include the 
acceptance of change 
within the pharmacy 
profession as well as public 
perceptions and awareness  
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Table 5– Influences on health professional and lay perspectives  
 Health Professional Perspectives  Lay Perspectives  
Individual level  • Experience, knowledge, skills and training 
• Self-efficacy and uncertainty 
• Perceived understanding and value of CP service to 
patients with LTCs 
• Conceptualisation of the wider role of CP  
• Illness perceptions, treatment beliefs and preferences 
• Disease factors, existing knowledge and experience of self-care  
(“expert patient”) and CP services 
• Existing support and perceived need 
• Expectations, acceptance and awareness of services and the role 
of the pharmacist 
Community 
Pharmacy 
Setting 
• Organisational cultures, resources, structures and 
management and commercial pressures  
• Physical locations and spaces  
• Role of organisational processes and operationalization of 
services 
• Physical locations, time and spaces  
• Perceived visibility and approachability of the pharmacist 
• Existing relationships and familiarity with the pharmacist 
• Knowledge and trust in skills and competence of pharmacists 
Local 
relationships 
and health care 
economies 
• Integration and collaboration with GPs and other HPs  
• Perceptions of role within wider health care team  
• Use of CP services validated by usual or trusted health provider 
• Satisfaction with existing relationships with GP or other health 
providers and accessibility of support and services  
• Perceptions and experience of “joined up” care and other local 
LTC services  
• Perceived need for pharmacist to “validate/sanction” use of GP 
time 
Wider health 
Care Context 
• Policy and political context, including contractual and 
financial incentives 
• Public and patient awareness and perceptions of the role 
of CP within the wider health care system 
• Awareness, perceptions and expectations of the role of CP in 
relation to traditional care roles and other health care providers  
• Awareness, expectations and experience of other sources of self-
care information and support 
Socio-cultural 
Context 
• Perceptions of medical hierarchies, power dynamics, 
labour divisions and boundaries of responsibility 
 
• Perceptions of medical hierarchies, power dynamics, labour 
divisions and boundaries of responsibilities 
• Community Support structures for LTCs; lay referral and support 
networks 
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Figure 1 – Literature search summary 
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Figure 2 - Understanding perceptions of the role of community pharmacy in facilitating care for people 
with LTCs: relationships between constructs and dynamic nature of process.  
 
 
 
 
 
 
 
